Physician
Sarojini Bose MD PA
Sarojini Bose MD PA was paid $39.56M by Medicaid between Jan 2018 and Dec 2024, across 113 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 26% of everything it billed.
33Billing provider infoSAROJINI BOSE MD PA
MCALLEN, TX 78504
MCALLEN, TX 78504
33aNPI1609066257assigned 07/30/2007
33bProvider typePediatrics Physician
28Total paid$39.56M
24GClaims1,833,731
24DCodes billed113
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#5 of 1,136
Median peer was paid$329K
This provider vs. median120×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,545 | $300K | |
| 2019 | 8,743 | $250K | |
| 2020 | 122,116 | $2.45M | |
| 2021 | 410,489 | $9.12M | |
| 2022 | 517,323 | $11.01M | |
| 2023 | 434,326 | $9.20M | |
| 2024incomplete | 330,189 | $7.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 313,935 | 275,681 | $10.47M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 22% | 213,309 | 196,950 | $8.54M |
| S8301 | Infection control supplies, not otherwise specified | 8.3% | 254,198 | 225,573 | $3.27M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.6% | 142,357 | 66,837 | $1.84M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.5% | 23,979 | 23,652 | $1.76M |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 18,991 | 18,702 | $1.44M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.6% | 29,791 | 28,219 | $1.41M |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.4% | 103,636 | 97,067 | $1.34M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 3.2% | 17,851 | 17,470 | $1.27M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.0% | 23,866 | 22,914 | $1.20M |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 2.7% | 105,685 | 45,441 | $1.08M |
| 87400 | 2.7% | 96,884 | 45,783 | $1.07M |
101 more codes
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.2% | 11,958 | $852K |
| 87430 | 1.8% | 55,549 | $726K | |
| 87428 | 1.5% | 9,719 | $606K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 97,360 | $596K |
| 99429 | <1% | 8,703 | $264K | |
| 99381 | <1% | 3,162 | $249K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,549 | $163K |
| 97802 | <1% | 42,536 | $112K | |
| 90461 | <1% | 28,084 | $105K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 13,577 | $101K |
| 87420 | <1% | 9,107 | $96K | |
| 99000 | <1% | 8,590 | $82K | |
| 99051 | <1% | 22,602 | $67K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,367 | $63K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,077 | $59K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,568 | $57K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,092 | $56K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 706 | $55K |
| 87807 | <1% | 5,124 | $53K | |
| 99382 | <1% | 484 | $42K | |
| 99383 | <1% | 427 | $35K | |
| 92567 | <1% | 3,003 | $35K | |
| 81000 | <1% | 10,383 | $32K | |
| 0071A | <1% | 837 | $32K | |
| 0001A | <1% | 819 | $29K | |
| 96160 | <1% | 14,102 | $26K | |
| 0072A | <1% | 648 | $25K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 302 | $24K |
| 90837 | Psychotherapy session, about an hour | <1% | 279 | $23K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 285 | $22K |
| 99384 | <1% | 237 | $22K | |
| 0002A | <1% | 523 | $18K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 427 | $16K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 266 | $15K |
| 99050 | <1% | 937 | $13K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 214 | $13K |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 1,255 | $12K |
| 97169 | <1% | 457 | $11K | |
| 83655 | <1% | 1,037 | $8K | |
| 80061 | Lipid panel | <1% | 847 | $7K |
| 81003 | <1% | 3,787 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 847 | $6K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,238 | $5K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 422 | $5K |
| 0081A | <1% | 94 | $3K | |
| 82947 | <1% | 965 | $3K | |
| 0003A | <1% | 68 | $3K | |
| 96161 | <1% | 1,343 | $3K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 25 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 163 | $2K |
| 0053A | <1% | 52 | $2K | |
| 86580 | <1% | 251 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 188 | $2K |
| 0073A | <1% | 44 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 26 | $1K |
| 0082A | <1% | 27 | $1K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 42,091 | $855.12 |
| 86308 | <1% | 176 | $750.57 | |
| 74018 | <1% | 18 | $429.42 | |
| 90480 | <1% | 17 | $398.43 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 513 | $284.14 |
| 90651 | <1% | 3,770 | $219.25 | |
| G9716 | Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason | <1% | 99 | $165.00 |
| 92587 | <1% | 38 | $51.80 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 425 | $17.85 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 13 | $7.15 |
| 90686 | <1% | 10,866 | $4.98 | |
| 90677 | <1% | 2,208 | $3.39 | |
| 84030 | <1% | 353 | $3.20 | |
| 96127 | <1% | 4,248 | $2.49 | |
| 90619 | <1% | 185 | $0.59 | |
| 90620 | <1% | 1,381 | $0.45 | |
| 90661 | <1% | 159 | $0.25 | |
| 90734 | <1% | 3,633 | $0.08 | |
| 90715 | <1% | 2,038 | $0.06 | |
| 90688 | <1% | 204 | $0.05 | |
| 90674 | <1% | 22 | $0.04 | |
| 90707 | <1% | 1,028 | $0.03 | |
| 90670 | <1% | 6,809 | $0.01 | |
| 90685 | 0% | 683 | $0.00 | |
| 90648 | 0% | 5,896 | $0.00 | |
| 90633 | 0% | 3,622 | $0.00 | |
| 90681 | 0% | 1,745 | $0.00 | |
| 90700 | 0% | 1,080 | $0.00 | |
| 91300 | 0% | 1,647 | $0.00 | |
| 90710 | 0% | 1,644 | $0.00 | |
| 91308 | 0% | 137 | $0.00 | |
| 90713 | 0% | 23 | $0.00 | |
| 90723 | 0% | 3,311 | $0.00 | |
| 90696 | 0% | 1,415 | $0.00 | |
| 90656 | 0% | 1,005 | $0.00 | |
| 91305 | 0% | 140 | $0.00 | |
| 90716 | 0% | 1,084 | $0.00 | |
| 90680 | 0% | 451 | $0.00 | |
| 90697 | 0% | 924 | $0.00 | |
| D1208 | Topical application of fluoride, excluding varnish | 0% | 339 | $0.00 |
| 91307 | 0% | 1,640 | $0.00 | |
| 90744 | 0% | 151 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 95 | $0.00 |
| 90698 | 0% | 171 | $0.00 | |
| 91301 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOSE, SAROJINI (OWNER)
| Provider | Location | Paid |
|---|---|---|
| DR Bose Industrial & Family Medicine PLLC | Mcallen, TX | $566K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.